Cholestatic Jaundice Management
Introduction to Treatment
- The primary treatment for severe cholestatic jaundice involves withdrawal of the suspected causative agent, followed by supportive care and specific interventions based on the underlying etiology, with liver transplantation reserved for end-stage disease, as recommended by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases 1
Supportive Care
- Patients with cholestatic jaundice should receive supplementation with medium chain triglycerides and fat-soluble vitamins, and optimization of nutritional state to avoid vitamin deficiency and malnutrition, as suggested by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases 1
Medication-Based Treatment
- Ursodeoxycholic acid (UDCA) at doses of 20-30 mg/kg/d is recommended to improve serum liver tests and histological appearance in patients with cholestatic jaundice, as suggested by the American Association for the Study of Liver Diseases 1
- Rifampicin may be used to alleviate pruritus in patients with cholestatic jaundice and is considered a first-line treatment for certain cases, according to the European Association for the Study of the Liver 1
- Corticosteroids may be beneficial in hypersensitivity-induced cholestasis, although evidence is limited 1
Surgical Interventions
- Partial biliary diversion and ileal exclusion may be considered for patients with PFIC1 and PFIC2, and liver transplantation is reserved for end-stage disease, as recommended by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases 1
Monitoring and Follow-Up
- Patients should be monitored with liver function tests within 7-10 days and until normalization (typically within 3 months) after withdrawal of the suspected causative agent, as suggested by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases 1, 2
- Drug-induced cholestatic liver injury is defined by elevated alkaline phosphatase (AP) >2× upper limit of normal (ULN) or ALT/AP ratio (both elevated above ULN) <2, and a diagnostic approach includes careful drug history and temporal relationship between drug intake and liver disease, exclusion of other causes of cholestasis, and laboratory monitoring 1, 2
- The European Association for the Study of the Liver recommends drug interruption when ALP >3× baseline or ALP >2× baseline combined with either total bilirubin >2× baseline or new onset of liver-related symptoms, and immediate withdrawal of the suspected drug is the primary treatment for drug-induced cholestasis 2, 1
- Patients with prolonged cholestasis require monitoring for progression to biliary cirrhosis, and rechallenge with the suspected drug should be avoided, as recommended by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver 2, 1
Epidemiology and Risk Factors
- Approximately 30% of all drug-induced liver injury cases are cholestatic, with a better prognosis than hepatocellular injury, as reported by the European Association for the Study of the Liver 1
- Psychotropic medications, herbal remedies, and supplements can trigger cholestatic injury, and genetic variations in hepatobiliary transporters can increase the risk of cholestatic liver injury 1
- The main mechanisms of drug-induced cholestatic liver injury include hepatocellular transporter inhibition, idiosyncratic/hypersensitivity reactions, and vanishing bile duct syndrome (VBDS) 1